Immunization in pregnancy safety surveillance in low and middle-income countries- field performance and validation of novel case definitions by Kochhar, S. (Sonali) et al.
Vaccine 37 (2019) 2967–2974Contents lists available at ScienceDirect
Vaccine
journal homepage: www.elsevier .com/locate /vacc ineImmunization in pregnancy safety surveillance in low and middle-
income countries- field performance and validation of novel case
definitionshttps://doi.org/10.1016/j.vaccine.2019.03.074
0264-410X/ 2019 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
⇑ Corresponding author at: Department of Public Health, Erasmus MC, University
Medical Center, Rotterdam, the Netherlands.
E-mail address: sonalikochhar@yaahoo.co.in (S. Kochhar).Sonali Kochhar a,b,c,⇑, Ed Clarke d, Alane Izu e, Kebonethebe Emmanuel Kekane – Mochwari e,
Clare L. Cutland e,f
aGlobal Healthcare Consulting, New Delhi, India
bDepartment of Public Health, Erasmus MC, University Medical Center, Rotterdam, the Netherlands
cDepartment of Global Health, University of Washington, Seattle, USA
dVaccines and Immunity Theme, MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, Gambia
eMedical Research Council: Respiratory and Meningeal Pathogens Research Unit, Department of Science and Technology/National Research Foundation: Vaccine Preventable
Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
fAfrican Leadership in Vaccinology Expertise (ALIVE), Faculty of Health Science, University of the Witwatersrand, South Africa
a r t i c l e i n f oArticle history:
Received 1 February 2019
Received in revised form 25 March 2019
Accepted 29 March 2019
Available online 20 April 2019
Keywords:
Immunisation
Vaccines
Safety
Pregnant women
Maternal immunisation
Adverse events following immunisation
AEFI
IMPRINT
Brighton Collaboration
GAIA
Case definitions, evaluation
Pregnancy outcomes
LMIC
Clinical trials
Preterm birth
Stillbirth
Hypertension
Gestational age
Ultrasound
Diagnostic certainty
Low resource settinga b s t r a c t
Background: A globally standardized approach in high and low and middle-income countries (LMIC) to
actively monitor the safety of vaccines for pregnant women during development and implementation
phases is critical. Brighton Collaboration’s (BC) Global Alignment of Immunization Safety Assessment
in Pregnancy (GAIA) project has developed globally standardized case definitions (CDs) of key obstetric
and neonatal terms for the assessment of safety of vaccines in pregnancy. CDs are categorized into levels
of diagnostic certainty, facilitating their use in varied settings. This study evaluates the field performance
of CDs in LMIC.
Methods: Data from pregnant participants of RCTs for trivalent inactivated influenza vaccine conducted
at Chris Hani Baragwanath Academic Hospital, South Africa (SA) between 2011 and 2013 were reviewed
retrospectively for preterm birth, stillbirth and hypertension CDs and the Gestational age assessment
(GA) algorithm. Data from an ongoing pneumococcal vaccine trial (conducted at MRC Unit, The
Gambia) were collected prospectively for GA.
Results: For GA, 600 mother-infant dyads from Gambia and 155 mother-infant dyads from SA were
reviewed. Level 2B (unsure LMP and US in 2nd trimester) was the most common level seen in Gambia
(63%) and level 3B1 (unsure LMP with physical examination) in SA (43%). Preterm deliveries had similar
results in SA. The pregnancy-induced hypertension definition performed well, with 96% (54/56) of cases
fulfilling ‘level 1’ for ‘preeclampsia with severe features’. 24 stillbirths were identified and 21 records
were reviewed; 73.3% (11/15) of the stillbirths classified as antepartum by attending physicians and
83.3% (5/6) of the intrapartum stillbirths did not fulfil the criteria for any level of certainty.
Conclusion: BC CDs for neonatal and maternal outcomes (preterm and hypertension) and GA were sensi-
tive, reliable and feasible to use in RCTs in SA and Gambia. Modifications to the stillbirth CD are required
to improve its usefulness in varied settings.
 2019 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction tetanus in low- and middle-income countries (LMIC) [1]. VaccinesImmunization in pregnancy is a well-established and effective
public health strategy utilized to prevent maternal and neonatalfor pregnant women against influenza and pertussis infection are
currently recommended, predominantly in high-income countries
(HIC) [1,2]. Meningococcal vaccines have been used widely in the
meningitis belt in Sub-Saharan Africa, including in pregnant
women. Immunization of pregnant womenmay provide protection
against infectious diseases for the pregnant women, the fetus
2968 S. Kochhar et al. / Vaccine 37 (2019) 2967–2974(through the placental transport of IgG antibodies) and infants too
young to receive routine childhood immunization (through pas-
sively immunizing infants, via the colostrum and breast milk and
indirectly through herd immunity) [1–5]. By preventing infection
in the mother, there is also an indirect protective effect of prevent-
ing transmission of infection to the infant (cocooning) [5]. This
strategy holds enormous promise to reduce vaccine-preventable
disease-related morbidity and mortality among pregnant women
and young infants [2–5]. This is particularly true in LMIC, where
the burden of vaccine-preventable infectious diseases is high and
health services access is limited [3,5]. Pregnant women are at
increased risk of morbidity and mortality associated with certain
infectious diseases e.g. influenza [2]. Pregnancies complicated by
infection are at higher risk of adverse pregnancy outcomes, includ-
ing stillbirth, spontaneous abortion, low birth weight and preterm
birth [2–5].
Promising new vaccines are being developed for use during
pregnancy including for respiratory syncytial virus, Group B strep-
tococcus, cytomegalovirus and monovalent pertussis [1,3,5].
Despite the potential benefits of immunization in pregnancy, there
is still reluctance by some health professionals to offer vaccines,
and by pregnant women to receive vaccines [3,6]. The safety of
vaccines administered to pregnant women is a key consideration
for the women, their families, communities, healthcare providers,
researchers, vaccine manufacturers, regulatory bodies and ethics
committees [3,5]. A globally harmonized approach to actively
monitoring the safety of vaccines used in pregnancy both during
the vaccine development and implementation phases is critical
[3,7,8]. The sensitive phase immediately post-vaccine licensure,
where safety concerns are likely to be seen, while effectiveness
data is becoming available [3,8], is a vital time to conduct active
safety monitoring, beyond passive surveillance. Harmonized data
collection ensures that safety data is comparable, whether it is col-
lected in clinical trials, observational studies or in pharmacovigi-
lance programs in HIC and LMIC. Combining multi-location data
sets would enhance the detection of important AEs associated with
pregnancy (e.g. preterm birth, stillbirth, neonatal infections, fetal
distress, congenital anomalies etc.) [3,5,7]. This will assist in
increasing confidence in and the uptake of immunization in preg-
nant women.
Safety assessment of vaccines for pregnant women requires a
real-time assessment of benefit versus risk [3,7]. Knowledge of
baseline outcome rates is essential for such assessments. While
progress is being made, knowledge of baseline rates of maternal
and neonatal outcomes in LMIC remain limited including stillbirth,
neonatal death and premature birth [3,8–10]. For example, even if
a vaccine decreases premature births by decreasing infections that
lead to this AE, these will still occur in pregnancies and may be
incorrectly reported as being related to the immunization in preg-
nancy. This makes early benefit-risk-analyses difficult and may
adversely impact an immunization in pregnant women program
regardless of whether there is any causal relationship between out-
come and immunization. Vaccine manufacturers and regulators
need the confidence that adverse events can be identified and doc-
umented consistently to determine the safety of vaccines in preg-
nancy [3,8–10].
Historically, case definitions (CDs) (i.e., a globally harmonized
set of criteria for the identification and assessment) of Adverse
Events Following Immunisation (AEFI) have not been standardized,
which resulted in poor comparability of safety data across vaccine
clinical trials and studies in the pre-and post-licensure periods
[3,7,8]. In vaccine safety, standardized CDs (which are reliable,
and practically implementable in different resource settings) and
guidelines for data collection, analysis, and presentation are
needed to further improve vaccine safety management, the qualityof vaccines and for a comparison and assessment with other vacci-
nes of the frequency and extent of AEFI [11]. This is especially true
as new vaccines are developed and introduced to large popula-
tions. Reporting details may vary depending upon available
resources, and diagnostic facilities in a geographic region, and
whether the information is from a clinical trial, epidemiologic
study, an individual case report of an AEFI or post-marketing
surveillance [7,11,12]. Therefore, CDs and guidelines, if developed
for global use, need to accommodate the varying quality of infor-
mation from different resource settings, given the widely differing
availability of tools, trained personnel and data collected to explore
an AE and make a diagnosis. Most AEs following pregnancy occur
within 48 hours of delivery [13], however, as many as 24% of all
births globally and 44% of births in sub-Saharan Africa are not
facility-based [14]. Data from delivery-related events, including
labor progress, delivery, possible complications and their precipi-
tating events are limited in unattended deliveries.
Global standardization would enable comparability of vaccine
safety data collected from HIC and LMIC (including from clinical
trials, epidemiologic studies, individual case reports, and surveil-
lance systems). Harmonized vaccine safety research will allow
the development of knowledge on the risks of immunization, and
enhance trust in immunization programs [7,11,12,15,16]. It is also
important to use the harmonized and applicable methodologies
(including case definitions and measurement of gestational age)
for studying health interventions in pregnancy and monitoring
pregnancy outcomes [3].
The Brighton Collaboration (BC) was formed in the year 2000 to
help overcome these shortcomings (see https://www.brightoncol-
laboration.org/). The BC case definitions (CDs) include criteria for
the verification of clinical events as ‘‘cases”, independent from
causality assessment of the AEFI [7,12]. BC CDs are evidence-
based tools which help to assign diagnostic certainty levels to clin-
ical events in the pre-and post-marketing surveillance of vaccines,
in the determination of background rates of particular events in a
given population and in measuring safety outcomes both prospec-
tively in randomized clinical trials and also retrospectively through
chart or other source document reviews [7,12,15]. BC CDs are
designed for diagnosis, monitoring, evaluation and surveillance.
They are not intended to guide patient care. The CDs are indepen-
dent from presumed causality assessment. Based on the availabil-
ity of personnel, clinical and diagnostic facilities, the diagnoses
may be established with a different degree of confidence according
to the resources available in different settings [16]. These differ-
ences are accounted for in the BC Levels of Diagnostic Certainty
which allow for consistent comparisons to be made irrespective
of the resources and diagnostics available [7]. Of importance, BC
definitions are recommended for use by the World Health Organi-
zation (WHO), the United State Food and Drug Administration (US
FDA), the US Centers for Disease Control and Prevention (CDC), the
European Medicines Agency (EMA), the European Centre for Dis-
ease Prevention and Control (ECDC) and other normative bodies
[10].
Ideally, newly developed CDs should be evaluated for their
applicability, reliability, specificity and sensitivity in their settings
of use. Where CD’s evaluation was done, researchers found that
small changes in the CD can have a large impact on its sensitivity,
the completeness and timeliness of reporting data accurately in
clinical trials and surveillance systems, and the CD’s appropriate-
ness for use in different resource settings [10,16,17]. There might
be concerns that collection of data required for the BC CDs may
add additional burden on investigators, and that the CDs may
require data not routinely available in routine care or randomized
controlled trials (RCTs) in low resource settings. The CDs need to be
applicable to both HIC and LMIC, and to achieve the stated purpose,
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implemented in the respective research, surveillance, and country
settings [11,12,17,18].
The Bill and Melinda Gates Foundation-funded Global Align-
ment of Immunization safety Assessment in pregnancy (GAIA) pro-
ject, was established in response to the WHO call for a globally
standardized approach to actively monitor the safety of immuniza-
tion for pregnant women programs with a specific focus on LMIC
needs [3,8]. GAIA project partners have developed a set of 25 glob-
ally harmonized CDs of key obstetric and neonatal terms for the
assessment of safety of vaccines in pregnant women [3]. Each CD
is categorized into multiple diagnostic certainty levels, facilitating
their use irrespective of the diagnostic resources available.
Enabling terms critical for the obstetric and neonatal CDs were also
developed to support investigators using the definitions (e.g. gesta-
tional age (GA) assessment algorithm).
WHO’s Global Advisory Committee on Vaccine Safety (GACVS)
recommended the evaluation and validation of the BC GAIA CDs,
guidelines and tools in the context of ‘‘real-world” clinical research
and observational studies to establish their applicability in LMIC,
where they need to be applied [19]. The GAIA CDs have undergone
limited field testing, particularly in LMIC [20]. The availability of
large data sets through completed and ongoing clinical trials con-
ducted by members of the Immunizing Pregnant women and
Infants network (IMPRINT) network provided an ideal platform
to assess their field applicability and evaluate and validate them.
This study aimed to evaluate the field performance of novel BC
GAIA CDs designed to harmonize safety monitoring for Immuniza-
tion in Pregnant Women in LMIC. Three BC CDs (preterm birth,
stillbirth and hypertension) [21–23] and one enabling term (the
GA algorithm) [21] were assessed.
These outcomes were chosen as they are common adverse preg-
nancy outcomes in low resource settings [24], there was a high
incidence of the outcomes in the RCTs, they required GA assess-
ment (a key feature of many of the CDs), or occurred within one
month of birth (were more likely to be captured in LMIC settings).
Intrapartum and antepartum stillbirth CDs were assessed. The
objectives of the study were to assess the applicability (what levels
of diagnostic certainty (levels 1–5) can be ascertained in these set-
tings), applicability utilizing the data routinely collected in RCT,
feasibility (practicality) of implementation, reliability (specific
aspects of the CDs and GA Algorithm are repeatedly interpreted
in the same way by different study staff in LMIC), and to systemat-
ically analyze discordant cases and to describe issues identified by
the clinical staff in applying the BC CDs and GA Algorithm in LMIC
research settings in SA and The Gambia.
The results of this study were used to propose edits and sugges-
tions for the improvement of the BC CDs for incorporation in the
regular BC review of the CDs as well as recommendations for
evidence-based clinical practice.2. Methods
2.1. Study participants and setting
Participants for this study were pregnant women participating
in randomized controlled clinical trials (RCTs) of vaccines during
pregnancy in two African countries, South Africa (SA) and The
Gambia.
The cohort of South African women utilized as the population
from which participants were selected has been described previ-
ously [25]. Briefly, HIV-uninfected and HIV-infected pregnant
women who were enrolled into RCTs for trivalent inactivated influ-
enza vaccine (NCT01306669, NCT01306682) conducted at the Res-
piratory and Meningeal Pathogens Research Unit at the Chris HaniBaragwanath Academic Hospital (CHBAH), Soweto, between 2011
and 2013, were eligible for this study. Medical records and
study-specific notes of mother-infant dyads that had at least one
of the outcomes of interest were reviewed retrospectively by med-
ical officers or clinical associates.
Women from The Gambia who were participants in an ongoing
maternal and neonatal pneumococcal vaccination trial
(NCT02628886, start date March 11, 2016) being conducted at
MRC Unit, The Gambia at the London School of Hygiene and Trop-
ical Medicine were eligible for the study. Data on gestational age
assessment were collected prospectively based on the GA
algorithm.
2.2. Study design and case selection
In SA, de-identified data from maternal/ fetal/ neonatal partici-
pants of the maternal influenza trials with the specific serious
adverse events (preterm birth, stillbirth and hypertension) were
extracted by local data managers in the database. Additional vari-
ables required for the BC CDs were abstracted from medical notes
onto specifically prepared clinical report forms and a REDCap
database.
During the clinical trials conducted in Respiratory and Menin-
geal Pathogens Research Unit, SA, the AE were classified by the
medical personnel who attended the delivery, according to stan-
dards used in the Obstetrics department. Selected cases in which
preterm birth, stillbirth and hypertension were considered to be
the final diagnosis were analyzed for sensitivity against the BC
GAIA CDs. In the RCTs conducted in SA, gestational age was
assessed using an algorithm which included symphysis-fundal
height (SFH), last menstrual period (LMP) and if available, ultra-
sound GA assessment. Ultrasound assessment of gestational age
was not offered routinely in SA due to resource constraints. Gesta-
tional age was determined at the time of enrollment into the vac-
cine trial and was used to determine the fetal gestational age in
order to assess the pregnant women’s eligibility for the RCT (as
vaccination is administered up to 34 weeks of gestation) and speci-
fic outcomes, such as preterm birth. Original trial databases were
utilized to identify participants who were diagnosed with at least
one of the three outcomes of interest, as recorded by attending
health care workers in medical records.
Utilizing the search methods, eligible clinical cases were pooled
and verified. Duplicate cases were removed. Only cases with writ-
ten documentation of a suspected or definite diagnosis were con-
sidered eligible for the study.
In The Gambia, data related to the GA algorithm were collected
prospectively from the cohort of expectant mothers enrolled in the
trial. Ultrasound facilities to determine gestational age were estab-
lished for the trial within a newly established platform for mater-
nal immunization studies in The Gambia. This aimed to maximise
the level of certainty achieved. There are limited ultrasound facil-
ities in the country. Although increasing, such assessments have
not routinely been available in public health centres and there is
limited availability in private health centres. Symphyseal-Fundal
height (SFH) determination is generally done for GA assessment.
600 pregnant women were recruited for the Prevenar 13 maternal
vaccination trial (PROPEL) and GA assessment was done for them.
Although vaccination was not undertaken until between 28 and
34 weeks gestation, the trial aimed to recruit expectant mothers
as early in pregnancy as possible based on the time they initially
booked at the government antenatal clinic. Early recruitment
aimed to enhance the accuracy and hence level of certainty of
the ultrasound-based assessment. Data on SFH both at initial
screening and also at the time of vaccination were also collected
by trial clinicians. When available, information on LMP was also
recorded. Anonymized data related to the GA algorithm collected
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validated clinical trial database for analysis.
2.3. Applying the Brighton Collaboration CDs
The databases contained reviewed cases with their unique par-
ticipant identification numbers (PID) and the respective informa-
tion on the symptoms and signs of the CDs and the GA
algorithm. No personal identifying information of the RCT partici-
pants was entered in the databases. The databases were password
protected, and access was limited to data entry and analysis per-
sonnel only. The data abstraction from medical records for assess-
ment of the level of diagnostic certainty for the CDs and GA
algorithm utilizing the BC definitions was done by the researchers
(clinical associates, professional nurses, investigators, medical offi-
cers) at each site, who had not previously been involved in the rou-
tine care of the participants. Independent of each other, they
reviewed the medical records in a blinded manner using the struc-
tured paper case report form (CRF).
In case of queries, they approached the study investigator at the
sites for clarification. The databases were checked for accuracy and
completeness with respect to the information on the criteria of the
CDs and GA algorithm by the site data manager and statistician.
For quality control purposes, an audit of 5 percent of the files
was randomly conducted by the medical officer or clinical associ-
ate. The study statistician analyzed the data to ascertain the high-
est level of certainty achieved by each participant for the relevant
definition(s).
In The Gambia, fields required for the determination of the level
of certainty of the gestational age assessment were extracted from
the clinical trial database and the proportion of participants in
whom a given level of certainty had been established determined
by the study statistician.
The BC event classification in 5 categories was done as follows
Event meets CD
(1). Level 1: Criteria as specified in the CD
(2). Level 2: Criteria as specified in the CD
(3). Level 3: Criteria as specified in the CD
Event does not meet CD
(4). Reported case with insufficient evidence to meet the CD
(5). Not a case
2.4. Statistical analysis
In SA, the descriptive statistical analysis of participant demo-
graphics included examinations of means, ranges, frequencies,
standard deviations, interquartile ranges, and percentages. The sta-
tistical packages Stata and R were used.
In The Gambia, the level of certainty related to the assessment
of GA, based on the data collected prospectively, was determined
for all participants enrolled in the trial. This was compared to the
level of certainty which would otherwise have been available to
the trial team had data available on the government antenatal card
held by the expectant mother been used. The analysis was descrip-
tive and based on the percentage of all participants falling into
each category.
2.5. Ethics
The study/trial protocols were reviewed and approved by the
applicable institutional review boards/ethics committees (Human
Research Ethics Committee (human) of the University of the Wit-
watersrand, Johannesburg, SA and the Gambia Government/MRC
Joint Ethics Committee, The Gambia).3. Results
In SA, 2 310 maternal participants were enrolled into the mater-
nal influenza trials, 2118 were HIV-uninfected and 194 were HIV-
infected. The baseline demographic characteristics and clinical fea-
tures of South African participants are provided in Table 1. The
study results are shown in Tables 2 and 3 and Fig. 1.
For GA assessment, 600 mother-infant dyads from The Gambia
and 155 mother-infant dyads from SA were reviewed and level 2B
(unsure LMP and US in 2nd trimester) was the most common level
seen in The Gambia (63%) and level 3B1 (unsure LMP with physical
examination) in SA (43%). Sixty-four premature deliveries were
reviewed in SA, 48.6% (31/64) fulfilled GAIA level 3B1 for gesta-
tional age assessment (Table 3). Demographic data were reviewed
for 89% (57/64) of the premature deliveries (Table 1) as some files
were not available for review (as they had been archived off-site or
were out of filing room for another study).
In SA, only one mother had a first-trimester ultrasound, which
is required for Gestational age assessment Level 1. Second-
trimester ultrasounds or first-trimester physical examinations
were available for 20.6% (32/155) participants, who fulfilled level
2. Three of these participants were downgraded from Level 2A-1
to Level 2B as the LMP and US did not correlate (14 days discrep-
ancy), so ‘certain LMP’ was amended to ‘uncertain LMP’. The major-
ity of cases met criteria according to level 3 (78.7%; 122/155) as
there was a lack of access to ultrasound examination in public
health care facilities during the Maternal Influenza trial recruit-
ment period and poor patient recall of LMP.
Prospectively collected data related to the assessment of GA
were available for 600 participants enrolled in the trial in The
Gambia. Based on having a first-trimester ultrasound, 8 of 600
(1.3%) participants had their gestational age assessed in the trial
with the highest level of certainty (Level 1). 379 of 600 (63.2%) of
participants had a second trimester (14 weeks to < 28 weeks)
ultrasound. However, all were assigned a 2B level of certainty in
the absence of the certain LMP data required for the higher level
2A level. The remaining 213 participants (35.5%) attained only
the lowest level (Level 3B) of certainty based on the defined GA
algorithm. While they all had a third-trimester ultrasound, the
absence of a certain LMP prevented them from being ascribed
the higher 3A certainty level. Classifying the level of certainty
achieved based on review of the antenatal card, 517/600 (86.2%)
achieved the lowest level of certainty (Level 3B) based on an uncer-
tain LMP and SFH, 71/600 (11.8%) achieved level 3A based on a first
trimester physical examination and 12/600 did not have data avail-
able to allow classification (Level 4).
Medical records of 56 South African women with ‘pregnancy-
induced hypertension’ were reviewed. Of these women, 96%
(54/56) were classified as having ‘preeclampsia with severe fea-
tures, level 10. The remaining 2 women had ‘gestational hyperten-
sion level 20.
There were 24 stillbirths (>28 weeks GA) identified in the par-
ticipants of the maternal influenza trials [25]. Of these, 87.5%
(21/24) files were reviewed for classification using the BC stillbirth
definition. Seventy-one percent (15/21) of the stillbirths had evi-
dence of maceration and intrauterine fetal death prior to the onset
of labor and were classified as antepartum stillbirths by attending
physicians. Of these, 73.3% (11/15) did not fulfil the criteria for any
level of certainty and were, therefore ‘unclassified antepartum
stillbirths’. There were six intrapartum stillbirths, one of whom
(16.7%) fulfilled any level of certainty.
All of the ‘unclassified’ antepartum and intrapartum stillbirths
fulfilled all but one criteria for the ‘level 2’ of certainty. Level 2
required gestational age of stillbirth to fulfil level 1 or 2 for the ges-
tational age requirement; however, all cases were classified as
Table 1
Demographics and baseline clinical features of South African women.
Mother characteristic
Number of women Overall HIV- negative
N = 2118
Overall HIV- positive
N = 194
Hypertension cohort
N = 56
Premature delivery cohort
N = 57
Mean age (Standard Deviation); years 26.1 (5.3) 28.1 (5.0) 25.5 (5.5) 25.2 (5.2)
Median body mass index (IQR) 27.6 (24.3, 31.7) 27.9 (24.9, 32.0) 29.0 (25.6, 32.6) 26.3 (23.2, 29.6)
Mean gestational age at enrolment (Standard
Deviation); weeks
27.0 (23.3, 31.0) 27.6 (24.9, 30.7) 27.0 (22.7, 30.7) 26.9 (22.4, 31.0)
Median gravidity (IQR) 2.0 (1.0, 3.0) 2.0 (2.0, 3.0) 2.0 (1.0, 2.2) 2.0 (1.0, 2.0)
Median parity (IQR) 1.0 (0.0, 1.0) 1.0 (1.0, 2.0) 0.0 (0.0, 1.0) 0.0 (0.0, 1.0)
Number of twin pregnancies (%) 55 (2.6) 5 (2.6) NA (NA) 1 (1.8)
Fetal outcomes and newborn characteristics
Number of fetal outcomes known N = 2027 N = 183 N = 56 N = 57
Number of normal vaginal deliveries (%) 1399 (69.0) 111 (60.7) 39 (69.6) 39 (68.4)
Number of caesarian section deliveries (%) 628 (31.0) 72 (39.3) 17 (30.4) 18 (31.6)
Number of preterm birth < 370/7 (%) 205 (10.1) 25 (13.7) 11 (19.6) 49 (86.0)
Overall median birth weight (range); kilograms 3.1 (2.8, 3.4) 3.0 (2.7, 3.3) 3.0 (2.6, 3.2) 2.1 (1.5, 2.6)
Overall number of low birth weight newborns (%) 255 (12.5) 29 (15.6) Information not
available
Information not available
Number of newborns died after delivery (%) 13 (8.2) 4 (30.8) 0(0) 2 (8.3)
Number of newborns admitted to neonatal
nursery (%)
129 (81.6) 9 (69.2) 5 (50.0) 16 (64.0)
Table 2
Gestational age assessment classification using the GAIA definition of mothers
enrolled in the Immunisation in Pregnant Women trials in South Africa and The
Gambia.
The Gambia
n (%) N = 600
South Africa
n (%) N = 155
Overall
n (%) N = 755
Level 1–1 0 (0) 0 (0) 0
Level 1–2 8 (1.3) 1 (0.7) 9 (1.2)
Level 2A-1 0 12 (7.7) 12 (1.6)
Level 2A-2 0 5 (3.2) 5 (0.7)
Level 2B 379 (63.2) 15 (9.7)# 394 (52.2)
Level 3A-1 0 7 (4.5) 7 (0.9)
Level 3A-2 0 37 (23.9) 37 (4.9)
Level 3A-3 0 3 (1.9) 3 (0.4)
Level 3A-4 0 4 (2.6)* 4 (0.5)
Level 3B-1 213 (35.5) 67 (43.2)$ 280 (37.1)
Level 3B-2 0 0 (0) 0
Level 3B-3 0 4 (2.6) 4 (0.5)
GA assessment levels amended:
# 3 moved from Level 2A-1 to Level 2B as there was a discrepancy of >10 days
between the EDD calculated using the LMP and EDD calculated using second-
trimester ultrasound. ‘Certain’ LMP amended to ‘Uncertain’ LMP.
* 3 moved from Level 2A-2 to Level 3A-4 as the difference between EDD from
LMP and physical examination was >7 days.
$ 11 moved from 3A to 2 to 3B-1 as the difference between EDD from LMP and
2nd-trimester physical examination was >14 days.
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tiary hospital and therefore did not fulfil the ‘non-attended deliv-
ery’ criteria in level 3 of certainty.Table 3
Level of certainty for Gestational age attained in preterm infants in South Africa.
Level of certainty achieved Overall N (%) N = 64 <28 wee
Level 1–1 0 0
Level 1–2 0 0
Level 2A-1 5 (7.8) 3 (27.2)
Level 2A-2 1 (1.6) 0
Level 2B 10 (15.6) 2 (18.2)
Level 3A-1 2 (3.1) 0
Level 3A-2 13 (20.3) 3 (27.3)
Level 3A-3 0 0
Level 3A-4 2 (3.1) 0
Level 3B-1 31 (48.4) 3 (27.3)
Level 3B-2 0 0
Level 3B-3 0 0If level 3 of the BC stillbirth CD was modified to allow for
attended deliveries, all the ‘unclassified’ antepartum and intra-
partum stillbirths would fulfil level 3 (see Table 4).3.1. Feasibility and reliability of the CDs
Data variables utilized in the CDs reviewed are routinely
recorded by attending medical staff in records from attended deliv-
eries in LMICs, therefore the collection of data for classification of
adverse events using the GAIA CDs is feasible and not resource-
intensive.
Implementation of the CDs and GA algorithm in Pharmacovigi-
lance reporting in SA and The Gambia, would be feasible, however,
the data reporting tools utilized in SA and The Gambia would
require some minor modifications to ensure that all required vari-
ables are collected. Training of personnel involved in routine PV
reporting would ensure that data review and collection are
standardized.
There were high levels of reliability and agreement between the
clinician’s diagnoses and the categorizations according to the BC
CD for preterm and hypertension and GA assessment but stillbirths
could not be classified easily with the current definition.3.2. Resources required and CRF completion
The case identification at the sites was primarily done by clini-
cal associate/ clinical officers, physicians, nurses and researchers.ks N = 11 28–33 weeks N = 19 34–36 weeks N = 34
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Fig. 1. Level of certainty distribution for gestational age for pregnant women included in maternal immunisation trials in The Gambia (n = 600) and South Africa (n = 155).
Table 4
Level of certainty for stillbirths from South African Maternal influenza immunisation cohort.
Antepartum
n (%)
N = 18
Intrapartum
n (%)
N = 6
Modified Antepartum #1*
n (%)
N = 18
Modified Intrapartum #1*
n (%)
n = 6
Modified Antepartum #2$
n (%)
N = 18
Modified Intrapartum #2$
n (%)
n = 6
Level 1 5 (27.8) 0 5 (27.8) 0 5 (27.8) 0
Level 2 2 (11.1) 0 2 (11.1) 0 2 (11.1) 0
Level 2A 0 0
Level 2B 11 (61.1) 6 (100)
Level 3 0 0 11 (61.1) 6 (1 0 0) 0 0
Unclassified 11 (61.1) 6 (100) 0 0 0 0
* Attended delivery accepted in level 3 of certainty.
$ Level 2A remains identical to current level 2, Level 2B is identical to current level 2, except GA level 3 is allowed.
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stand and utilize the CDs and GA algorithm. Time taken to review
the medical records was dependent on the clinical course of dis-
ease progression and care of the mother and/ or foetus/ neonate.
Once the complete file had been reviewed (10–60 min), comple-
tion of the case report form took less than 10 min.
All study staff at the SA and Gambian research centers found the
CRFs easy to complete.4. Discussion
The consistent determination of GA during clinical trials of
maternal vaccines as well as within post-implementation pharma-
covigilance programmes is essential. The timing of vaccine admin-
istration during pregnancy is by definition dependent on having
knowledge of the gestational age of the expectant mother. The time
window within which the administration of newly licensed mater-
nal vaccines is recommended in the future is likely to be narrow –
being based on safety data generated in the tightly regulated clini-
cal trial setting. For this reason, the ability to determine gestational
age accurately will become increasingly key to program implemen-
tation. Furthermore, the detection of post-implementation safety
signals, such as the occurrence of preterm delivery and infantsborne small for gestational age is absolutely dependent on the
robustness with which gestational age is initially assessed. The
prospective collection of data related to the GA algorithm in a clin-
ical trial in The Gambia highlighted a number of challenges in
determining gestational age with the highest degree of certainty,
even prospectively. While we aimed to recruit early in pregnancy
in order to undertake a first-trimester ultrasound, few women in
the trial presented to government antenatal services in the first tri-
mester. Consequently, only a little over 1% of participants had the
first-trimester ultrasound required to achieve the highest level of
certainty. Of the remaining participants, nearly two-thirds had a
second-trimester ultrasound. In The Gambia, it was found that cer-
tainty regarding LMP date was uncommon thus reducing the level
of certainty otherwise achieved based on the second-trimester
ultrasound. In the remaining third of participants, the lowest level
of certainty was achieved based on the reliance on the SFH in the
third trimester. This is the current primarymechanism of determin-
ing gestational age in The Gambia although ultrasound is being
gradually phased in. Consequently, the ultrasound markedly
enhanced the level of certainty related to gestational age achieved
compared to that which would normally be available.
Retrospective case identification required a search through the
archived study files, as electronic health records are not commonly
available in LMIC. ICD coding, if used, was accurate in identifying
S. Kochhar et al. / Vaccine 37 (2019) 2967–2974 2973the adverse event, but a manual review of medical records was
required to abstract all variables required for CD completion.
The study design showed strengths: several methods (including
ICD-10 codes and electronic search with pre-defined terms of the
discharge summaries) were used to identify cases. The investiga-
tors involved in case ascertainment were independent of those
providing clinical care to the study participants and during the
data entry and case evaluation were blinded to the discharge diag-
nosis. The study utilized both prospective and retrospective review
of the GA algorithm in clinical trials in LMIC and showed similar
sensitivity, reliability and feasibility. The simple study design can
be replicated, allowing comparison of clinical data across different
settings and countries.
The study limitations include the fact that in a retrospective
review of study participants charts, it is not possible to have a com-
plete understanding of the clinician’s decision making. Incomplete
documentation of data in the records can lead to underreporting of
cases.
There were no major issues identified in utilizing the preterm
birth and hypertension CDs and the GA algorithm in the retrospec-
tive analysis in the RCTs in SA and for the GA algorithm in the
prospective analysis in the ongoing RCT in The Gambia.
Seventy-one percent of the identified stillbirths (including
antepartum and intrapartum) could not be classified, due to limita-
tions in the CD. The main reason for not classifying stillbirths was
that data for a participant did not fit into a level of diagnostic cer-
tainty. Although facility-based deliveries have increased in LMICs,
resources are still limited to accurately assess GA. The current still-
birth definition does not adequately allow for the classification of
facility-based deliveries with level 3 GA. The BC GAIA CD for still-
birth could be improved in order to adequately capture cases with
diagnostic certainty, especially in LMIC, where identification of
potential immunization in pregnancy-related safety outcomes
can be challenging. These CDs could be utilized to determine the
background rates of the outcomes of interest in the study popula-
tion and the sample size of studies for active surveillance. It would
also be useful to assess the applicability of the case definitions for
observational studies.
A recent publication demonstrated that it was feasible to imple-
ment BC GAIA CDs (ten obstetric and neonatal CDs) at sites with
very limited resources (one government-funded district hospital
and 15 government-accredited health centers at the Health and
Demographic Surveillance Site (IMHDSS) in Uganda. IMHDSS con-
sists of 65 villages located 120 km from Kampala). Higher level
facilities were able to diagnose higher levels of certainty. Most sites
were able to classify cases with at least one level of certainty [26].5. Conclusion
The diagnosis of preterm birth, hypertension and the enabling
term (Gestational Age (GA) Assessment Algorithm could be made
using the BC GAIA CDs in LMICs with high reliability, minimum
selection bias and utilizing the data routinely collected in the RCTs
in LMIC. The BC GAIA stillbirth definition requires modification to
address the issues encountered. A suggestion is to either split level
2 into 2A and 2B, where 2A is identical to current level 2, and level
2B allows for GA level 3; or include attended deliveries in level 3.
The second option underestimates the certainty and option
2A/2B is recommended. The BC GAIA CDs are a plausible standard,
are easily applicable and useful for capturing a majority of cases of
preterm birth, hypertension and Gestational Age (GA) Assessment
in clinical trials conducted in LMIC settings in SA and The Gambia.
The CDs utilization is an evidence-based method for the ascertain-
ment of cases and can help to improve data quality, comparability,
pooling and standardization.Funding
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